This trial is comparing the two most common types of hemodialysis access: Human Acellular Vessel (HAV) and arteriovenous fistula (AVF).
2 Primary · 13 Secondary · Reporting Duration: 12, 24, and 60 months post SA creation
Active Control
Experimental Treatment
240 Total Participants · 2 Treatment Groups
Primary Treatment: Human Acellular Vessel (HAV) · No Placebo Group · Phase 3
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: